ATTR-CM is a rare but debilitating cardiac condition whose symptoms overlap with more common disorders leading to under- and delayed-diagnosis
This screening program will help improve early detection of ATTR-CM in the community by increasing access to the CA-4F algorithm
CA-4F is a computational algorithm that estimates the likelihood of equivocal or positive finding for ATTR-CM on Tc-99 m PYP. It is encoded in medical device software deployed at Ensho data labs and applied to the electronic health records of requesting cardiologists as a service. The average community cardiologists can expect CA-4F to predict 20 patients per year to have a >10% probability of positive findings for ATTR-CM on Tc-99 m PYP. Reports for each patient will be distributed through Compass ↗︎.
CA-4F Receiver Operating Curve
Cardiologists with a community practice, timely access to Tc-99 m PYP and a compatible EMR system are eligible participate. Compatible EMR systems include:
Contact email@example.com to request a data linkage with an EMR system not listed above.
This sponsored screening program is supported by Pfizer Canada. No patient-identifiable information will be shared with the program sponsor.